GlobeNewsWire
17 Aug 2026, 12:52 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The USPTO issued a Notice of Allowance for a patent covering the commercial formulation of ART27.13, potentially extending protection through 2041. — Long-term IP protection is a critical value driver for clinical-stage biotech companies, reducing future competition risk.
+0.60Interim Phase 2 CAReS trial data showed that patients on the highest dose of ART27.13 achieved an average 6% weight gain, while placebo patients lost ~5%. — Strong clinical efficacy in a market with no FDA-approved treatment for cancer anorexia suggests high commercial potential.
+0.50Initial results from the Phase 2 DREAM study for glaucoma or ocular hypertension are anticipated in the fourth quarter of this year. — Creates a near-term catalyst for the stock, though the impact depends on the actual data release.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company received a Notice of Allowance for a patent extending protection for its lead drug ART27.13 through 2041.
Mentioned only as the original developer of the drug ART27.13 without any current impact on its business.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Accesswire
3h ago
